125 related articles for article (PubMed ID: 9523231)
1. Innovative therapy for chronic myelogenous leukemia.
Miller JS
Hematol Oncol Clin North Am; 1998 Feb; 12(1):173-206. PubMed ID: 9523231
[TBL] [Abstract][Full Text] [Related]
2. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
3. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
5. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
Huang H; Chen Y; Chen W; Wu Y
Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
Corsetti MT; Lerma E; Dejana A; Cavaliere M; Figari O; Vassallo F; Abate M; Luchetti S; Piaggio G; Parodi C; Li Pira G; Manca F; Carella AM
Exp Hematol; 2000 Jan; 28(1):104-11. PubMed ID: 10658682
[TBL] [Abstract][Full Text] [Related]
8. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow transplantation for leukemia.
Stuart RK
Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
[TBL] [Abstract][Full Text] [Related]
10. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplantation for the treatment of chronic myelogenous leukemia.
Bhatia R; Forman SJ
Hematol Oncol Clin North Am; 1998 Feb; 12(1):151-72. PubMed ID: 9523230
[TBL] [Abstract][Full Text] [Related]
12. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
13. Autografting for chronic myelogenous leukemia.
Bhatia R; Verfaillie CM
Curr Opin Hematol; 1995 Nov; 2(6):436-43. PubMed ID: 9372033
[TBL] [Abstract][Full Text] [Related]
14. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia as an immunological target.
Lim SH; Coleman S
Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
[TBL] [Abstract][Full Text] [Related]
17. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
18. Ribozyme mediated therapy for chronic myelogenous leukemia.
Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
[No Abstract] [Full Text] [Related]
19. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
20. [Autologous bone marrow transplantation for CML].
Nagamura F; Nagamura-Inoue T
Nihon Rinsho; 2001 Dec; 59(12):2369-74. PubMed ID: 11766341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
